1.0501
2.95%
+0.0301
After Hours:
1.0501
Oragenics Inc stock is currently priced at $1.0501, with a 24-hour trading volume of 9,431.
It has seen a +2.95% increased in the last 24 hours and a -28.56% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.02 pivot point. If it approaches the $1.05 resistance level, significant changes may occur.
Previous Close:
$1.02
Open:
$1.02
24h Volume:
9,431
Market Cap:
$4.60M
Revenue:
-
Net Income/Loss:
$-10.15M
P/E Ratio:
-0.1801
EPS:
-5.83
Net Cash Flow:
$-8.62M
1W Performance:
-0.93%
1M Performance:
-28.56%
6M Performance:
-72.94%
1Y Performance:
-62.50%
Oragenics Inc Stock (OGEN) Company Profile
Name
Oragenics Inc
Sector
Industry
Phone
813-286-7900
Address
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
Oragenics Inc Stock (OGEN) Latest News
S&P 500 Edges Lower; ADT Posts Upbeat Earnings
Benzinga
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Nasdaq Down 50 Points; US Crude Stocks Rise By 4.2M Barrels
Benzinga
Dow Dips 200 Points; TJX Posts Upbeat Sales
Benzinga
Why Beyond Meat Shares Are Trading Higher By Around 56%; Here Are 20 Stocks Moving Premarket
Benzinga
Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Oragenics Inc Stock (OGEN) Financials Data
Oragenics Inc (OGEN) Net Income 2024
OGEN net income (TTM) was -$10.15 million for the quarter ending September 30, 2023, a +29.26% increase year-over-year.
Oragenics Inc (OGEN) Cash Flow 2024
OGEN recorded a free cash flow (TTM) of -$8.62 million for the quarter ending September 30, 2023, a +44.11% increase year-over-year.
Oragenics Inc (OGEN) Earnings per Share 2024
OGEN earnings per share (TTM) was -$4.67 for the quarter ending September 30, 2023, a +33.48% growth year-over-year.
About Oragenics Inc
Oragenics, Inc. focuses on developing antibiotics against infectious diseases and treatments for oral mucositis. It is developing OG716, an antibiotic product candidate, which is in nonclinical testing for healthcare-associated infections, as well as other homolog antibiotic product candidates. The company is also developing AG013, which is in Phase II clinical trial for the treatment of oral mucositis in cancer patients. Its product candidates also comprise LPT3-04, a naturally occurring dietary substance for weight loss; and SMaRT Replacement Therapy, a topical treatment applied to the teeth to protect against tooth decay. Oragenics, Inc. has collaboration agreements with Intrexon Corporation and its subsidiary, Intrexon Actobiotics NV to develop AG013 as a potential treatment of oral mucositis for cancer patients. It also has license agreements with LPThera LLC to develop LPT3-04, a weight-loss product candidate; and Texas A&M University System for access to new homologs of the lantibiotic Mutacin 1140 (MU1140) and other lantibiotics, as well as holds licenses from the University of Florida Research Foundation, Inc. for MU1140 product candidates. The company was formerly known as Oragen, Inc. Oragenics, Inc. was founded in 1996 and is headquartered in Tampa, Florida.
Cap:
|
Volume (24h):